TNF and infection: Our study shows that the unadjusted incidence of hospitalizations for infection was 3.6 per 100 patient-years for tofacitinib, compared with 2.2 and 2.5 per 100 patient-years in individuals using TNFi and non-TNF biologics, respectively.